+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Direct to Consumer Microbiome Analyzing Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 To 2029

  • PDF Icon

    Report

  • 106 Pages
  • November 2021
  • Region: Global
  • Acute Market Reports
  • ID: 5614567

Direct to consumer microbiome analyzing market to exhibit dynamic growth during the forecast period


The global direct to consumer microbiome analyzing market is growing efficiently, expected to grow at a CAGR of 11.8%. Globally, growing prevalence of chronic diseases along with gut infections has significantly increased the revenue of microbiome testing kits. New product launches along with raised funding for genome testing, and promising pipeline microbiome analyzing products in the DNA testing industry are factors driving the overall growth of direct to consumer microbiome analyzing market globally.

Gut microbiome test kits segment is expected to register higher growth by the end of 2029


Advancement in diagnostic testing along with sequencing-based clinical microbiome analyzing will enhance the future growth. Direct to consumer DNA testing is expanding significantly, has the capability to detect specific infections, lifestyle diseases, and gut conditions including irritable bowel syndrome and inflammatory bowel disease. For e.g. SmartGut (uBiome, Inc.), it is the world’s first sequencing-based clinical microbiome test. The global giants are investing for further R&D and are encouraging the commercialization of these sample kits in partnerships with smaller organizations to meet the active demand in future.

Expansion of services at home for gut microbiome testing to witness a significant CAGR


Increasing popularity of DNA testing kits along with services provided at home on a global level are notable factors expected for the growth of the market. Citizen scientists around the world are learning about their microbiomes. These kits are useful for various disease indications and applications including diarrhea, irritable bowel syndrome, inflammatory bowel disease, Crohn’s disease and ulcerative colitis, obesity, type 2 diabetes, chronic kidney disease, cardiovascular disease and many others. The genetics industry is now familiar with the consumer interest in microbiome testing as an opportunity, and a number of top commercial laboratories are marketing these test kits directly on a global level, mainly in the U.S. and Europe market.

Increasing population, new FDA approval and the presence of top players holds the U.S. in dominant position


In 2020, North America generated maximum revenue share in the direct to consumer microbiome analyzing market due to an increase in expansion of test kits along with raising awareness about new technology with improved outcomes at low cost. Rising home care services along with enhanced reimbursement structure will drive the growth in the near future. For e.g. In Dec 2019, direct-to-consumer DNA and microbiome test were launched in Europe. Atlas Biomed expanded its consumer-oriented DNA and gut microbiome tests with combined analysis on the corporation’s health program. Nevertheless, huge pipeline products, less awareness, accuracy along with data security and FDA regulations are factors restraining the overall growth of the market.

Increased research and development with strong product pipelines in the developed regions


Major players in the direct to consumer microbiome analyzing market are uBiome, Inc., Viome, Inc., Atlas Biomed and others. Major top organizations and DNA testing and research centers are developing smart technologies with integrated systems. Acquisitions, partnerships and enhanced R&D will improvise the expansion of direct to consumer microbiome analyzing market in the developing nations in near future.

Historical & Forecast Period

This study report represents analysis for each segment from 2019 to 2029 considering 2020 to be the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period from 2021 to 2029.

The current report also comprehends qualitative and qualitative market valuation factors such as key market drivers, market trends, restraints and opportunities that gives a better market understanding of the overall direct to consumer microbiome analyzing market. Additionally, the global report also comprises graphical representation of competitive landscape based on their market initiatives and strategies, product portfolio and business strengths.

Key questions answered in this report
  • What are the current market trends and dynamics in the direct to consumer microbiome analyzing market and valuable opportunities for emerging players?
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which product type segment holds a larger market share and why?
  • Are low and middle-income economies investing in the direct to consumer microbiome analyzing market?
  • What is the market trend and dynamics in emerging markets such as Asia Pacific, Latin America and Middle East & Africa?


This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Preface
1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Market Segmentation
1.3. Research Scope
1.4. Research Methodology
1.4.1. Phase I - Secondary Research
1.4.2. Phase II - Primary Research
1.4.3. Phase III - Expert Panel Review
1.4.4. Assumptions
1.5. Market Segmentation
Chapter 2. Executive Summary
2.1. Global DCMA Market Portraiture
2.2. Global DCMA Market, By Product Type, 2020 (US$ Mn)
2.3. Global DCMA Market, By Application, 2020 (US$ Mn)
2.4. Global DCMA Market, by Geography, 2020 vs. 2029 (Value %)
Chapter 3. Global Direct To Consumer Microbiome Analyzing (DCMA) Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. DCMA Market Technologies: Future Trends
3.3. Current Scenario: New Product Launches, High Prevalence For Parkinson’s Disease
3.4. Challenges
3.5. Opportunities
3.6. Attractive Investment Proposition, by Geography, 2020
3.7. Competitive Landscape
3.7.1. Competitive Landscape, by Key Players, 2020
Chapter 4. Global Direct To Consumer Microbiome Analyzing (DCMA) Market, by Product Type, 2019 - 2029 (US$ Mn)
4.1. Overview
4.2. Gut Microbiome Test Kits
4.3. Other Microbiome Testing Kits & Health Sample Kits
Chapter 5. Global Direct To Consumer Microbiome Analyzing (DCMA) Market, By Application, 2019 - 2029 (US$)
5.1. Overview
5.2. Infections
5.3. Gut Conditions
5.4. Metabolic Disorders
5.5. Cardiovascular Disease
5.6. Others
Chapter 6. Global Direct To Consumer Microbiome Analyzing (DCMA) Market, by Geography, 2019 - 2029 (US$ Mn)
6.1. Overview
6.2. North America DCMA Market Analysis, 2019 - 2029
6.2.1. North America DCMA Market, By Product Type, 2019 - 2029 (US$ Mn)
6.2.2. North America DCMA Market, By Application, 2019 - 2029 (US$ Mn)
6.2.3. North America DCMA Market, by Country, 2019 - 2029 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe DCMA Market Analysis, 2019 - 2029
6.3.1. Europe DCMA Market, By Product Type, 2019 - 2029 (US$ Mn)
6.3.2. Europe DCMA Market, By Application, 2019 - 2029 (US$ Mn)
6.3.3. Europe DCMA Market, by Country, 2019 - 2029 (US$ Mn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific DCMA Market Analysis, 2019 - 2029
6.4.1. Asia Pacific DCMA Market, By Product Type, 2019 - 2029 (US$ Mn)
6.4.2. Asia Pacific DCMA Market, By Application, 2019 - 2029 (US$ Mn)
6.4.3. Asia Pacific DCMA Market, by Country, 2019 - 2029 (US$ Mn)
6.4.3.1. Japan
6.4.3.2. China
6.4.3.3. Rest of APAC
6.5. Latin America DCMA Market Analysis, 2019 - 2029
6.5.1. Latin America DCMA Market, By Product Type, 2019 - 2029 (US$ Mn)
6.5.2. Latin America DCMA Market, By Application, 2019 - 2029 (US$ Mn)
6.5.3. Latin America DCMA Market, by Country, 2019 - 2029 (US$ Mn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East & Africa (MEA) DCMA Market Analysis, 2019 - 2029
6.6.1. MEA DCMA Market, by Product Type, 2019 - 2029 (US$ Mn)
6.6.2. MEA DCMA Market, By Application, 2019 - 2029 (US$ Mn)
6.6.3. MEA DCMA Market, by Region, 2019 - 2029 (US$ Mn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA
Chapter 7. Company Profiles
7.1. uBiome, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Viome, Inc.
7.3. Atlas Biomed Group Limited
7.4. Quantbiome, Inc. (Thryve Personalize)
7.5. FINCH THERAPEUTICS
7.6. MaaT Pharma
7.7. Kallyope Inc.

Companies Mentioned

  • uBiome Inc.
  • Viome Inc.
  • Atlas Biome.